Fezakinumab, an anti-IL-22 antibody, has been shown in the IIa randomized, double-blind clinical trial on adults with moderate to severe AD to be well tolerated and to have sustainable improvements after the last dose [55]. The gene discussed is IL22; the disease is Alzheimer disease.